IRIX Iridex (IRIX) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001006045
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter
What the filings say about IRIX
Insiders, 180 days
+$31.4K net bought
1 buyer
Iridex insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, IRIDEX CORP insiders bought a net $31.4K of stock across 227 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 110 earlier Form 4 trades (code P or S) here by this insider (110 buys), the last on Sep 14, 2026.
- -26.6% median (-10.4% mean) 90-day return after 27 previous buys.
- The trade is 4.3% of the 185,306 shares held after it.
- No other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Dizon Romeo R bought about $5.0K of IRIX on Sep 16, 2026; 13 funds added in the latest 13F quarter.Context
- 109 earlier Form 4 trades (code P or S) here by this insider (109 buys), the last on Sep 10, 2026.
- -27.2% median (-11.2% mean) 90-day return after 28 previous buys.
- The trade is 1.3% of the 177,406 shares held after it.
- No other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Dizon Romeo R bought about $1.5K of IRIX on Sep 14, 2026; 13 funds added in the latest 13F quarter.Context
- 108 earlier Form 4 trades (code P or S) here by this insider (108 buys), the last on Aug 24, 2026.
- -27.9% median (-11.8% mean) 90-day return after 29 previous buys.
- The trade is 2.9% of the 175,052 shares held after it.
- No other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Dizon Romeo R bought about $3.5K of IRIX on Sep 10, 2026; 13 funds added in the latest 13F quarter.Context
- 106 earlier Form 4 trades (code P or S) here by this insider (106 buys), the last on Jun 12, 2026.
- -28.5% median (-12.5% mean) 90-day return after 30 previous buys.
- The trade is 0.8% of the 164,584 shares held after it.
- No other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Dizon Romeo R bought about $973 of IRIX on Aug 24, 2026; 13 funds added in the latest 13F quarter.Context
- 106 earlier Form 4 trades (code P or S) here by this insider (106 buys), the last on Jun 12, 2026.
- -28.5% median (-12.5% mean) 90-day return after 30 previous buys.
- The trade is 3.2% of the 169,952 shares held after it.
- No other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Dizon Romeo R bought about $4.0K of IRIX on Aug 24, 2026; 13 funds added in the latest 13F quarter.227 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$31.4K over 180 days
+$15.0K over 90 days
more than 69% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 80% of Medical Devices
Revenue
+8.2% year over year
below 55% of Medical Devices
Margin
-8.4% net margin
more than 58% of Medical Devices
Buybacks
no share repurchases reported
Short interest
1.3% of the float short (float per yahoo 2026-10-26) · 3.5 days to cover · settled 2026-09-30
below 75% of Medical Devices
What changed in the last 30 days
Oct 7Insider Lin Shih-Yao David bought $1.3M (90 trades, Mar 25, 2025 to Mar 30)
Watch IRIX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-31.2%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns IRIX: institutional holders (13F)
13F holdings, latest reported quarter
514,593 sh
$589.2K
423,542 sh
$485.0K
305,193 sh
$349.4K
180,451 sh
$206.6K
138,960 sh
$159.2K
Congress trades in IRIX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
IRIX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
IRIX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$95.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$129.1K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$15.5K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$460.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$17.7K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$15.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $31.4K bought by insiders over 180 days, 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
IRIX financials
Revenue growth
+8.2%
XBRL, annual
Net margin
-8.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$51.6M
four quarters, 2025-06-29 to 2026-07-04
Revenue, TTM IRIX
| FY Jan 2026 | $52.7M |
| FY Dec 2024 | $48.7M |
| FY Dec 2023 | $51.9M |
| FY Dec 2022 | $57.0M |
| FY Jan 2022 | n/a |
| Jul 2026 | $12.6M |
| Apr 2026 | $11.8M |
| Jan 2026 | $14.7M |
| Sep 2025 | $12.5M |
| Jun 2025 | $13.6M |
| Mar 2025 | $11.9M |
| Dec 2024 | $12.7M |
| Sep 2024 | $11.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-6.9%
net income over revenue, 2025-06-29 to 2026-07-04
Net margin, TTM IRIX
| FY Jan 2026 | -8.4% |
| FY Dec 2024 | -18.3% |
| FY Dec 2023 | -18.5% |
| FY Dec 2022 | -13.2% |
| FY Jan 2022 | n/a |
| Jul 2026 | -10.1% |
| Apr 2026 | -4.4% |
| Jan 2026 | -1.2% |
| Sep 2025 | -12.6% |
| Jun 2025 | -7.3% |
| Mar 2025 | -14.2% |
| Dec 2024 | -6.6% |
| Sep 2024 | -16.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$2.0M
operating cash flow minus capex, 2025-06-29 to 2026-07-04
Free cash flow, TTM IRIX
| FY Jan 2026 | -$2.3M |
| FY Dec 2024 | -$7.3M |
| FY Dec 2023 | -$6.9M |
| FY Dec 2022 | -$9.8M |
| FY Jan 2022 | $8.0M |
| Jul 2026 | $124.0K |
| Apr 2026 | -$1.4M |
| Jan 2026 | $483.0K |
| Sep 2025 | -$1.2M |
| Jun 2025 | -$410.0K |
| Mar 2025 | -$1.2M |
| Dec 2024 | -$1.2M |
| Sep 2024 | -$3.1M |
At each fiscal year end
Single quarter
Debt to equity
0.74x
long-term 2024-12-28 (18 months older than the period end) plus current 2024-12-28 (18 months older than the period end); equity 2026-07-04
Debt to equity IRIX
| FY Jan 2026 | 0.55x |
| FY Dec 2024 | 1.29x |
| FY Dec 2023 | 0.03x |
| FY Dec 2022 | 0.02x |
| FY Jan 2022 | 0.01x |
| Jul 2026 | 0.74x |
| Apr 2026 | 0.57x |
| Jan 2026 | 0.55x |
| Sep 2025 | 0.58x |
| Jun 2025 | 0.45x |
| Mar 2025 | 3.17x |
| Dec 2024 | 1.29x |
| Sep 2024 | 1.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.64x
TTM operating cash flow over long-term 2024-12-28 (18 months older than the period end) plus current 2024-12-28 (18 months older than the period end)
Cash flow to debt IRIX
| FY Jan 2026 | -0.78x |
| FY Dec 2024 | -2.70x |
| FY Dec 2023 | -21.62x |
| FY Dec 2022 | -30.51x |
| FY Jan 2022 | 26.34x |
| Jul 2026 | -0.64x |
| Apr 2026 | -0.85x |
| Jan 2026 | -0.78x |
| Sep 2025 | -1.46x |
| Jun 2025 | -2.17x |
| Mar 2025 | -2.51x |
| Dec 2024 | -2.70x |
| Sep 2024 | -2.60x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-73.1%
TTM net income over average of 2025-06-28 and 2026-07-04
Return on equity IRIX
| FY Jan 2026 | -126.4% |
| FY Dec 2024 | -153.4% |
| FY Dec 2023 | -71.5% |
| FY Dec 2022 | -37.2% |
| FY Jan 2022 | n/a |
| Jul 2026 | -73.1% |
| Apr 2026 | -117.3% |
| Jan 2026 | -126.4% |
| Sep 2025 | -139.3% |
| Jun 2025 | -105.7% |
| Mar 2025 | -194.3% |
| Dec 2024 | -153.4% |
| Sep 2024 | -150.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-12.1%
TTM net income over average of 2025-06-28 and 2026-07-04
Return on assets IRIX
| FY Jan 2026 | -15.2% |
| FY Dec 2024 | -28.0% |
| FY Dec 2023 | -24.9% |
| FY Dec 2022 | -16.6% |
| FY Jan 2022 | n/a |
| Jul 2026 | -12.1% |
| Apr 2026 | -10.5% |
| Jan 2026 | -15.2% |
| Sep 2025 | -17.4% |
| Jun 2025 | -17.3% |
| Mar 2025 | -20.9% |
| Dec 2024 | -28.0% |
| Sep 2024 | -33.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital IRIX
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Jan 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-17.4%
operating income (EBIT proxy) over average of 2025-06-28 and 2026-07-04 minus current liabilities
Return on capital employed IRIX
| FY Jan 2026 | -18.0% |
| FY Dec 2024 | -48.8% |
| FY Dec 2023 | -39.0% |
| FY Dec 2022 | -22.9% |
| FY Jan 2022 | n/a |
| Jul 2026 | -17.4% |
| Apr 2026 | -15.5% |
| Jan 2026 | -18.0% |
| Sep 2025 | -20.2% |
| Jun 2025 | -21.3% |
| Mar 2025 | -28.0% |
| Dec 2024 | -48.8% |
| Sep 2024 | -55.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing IRIX
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Jan 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$11.2M
market value at close 2026-10-26 on 2026-08-13 shares, plus long-term 2024-12-28 (18 months older than the period end) plus current 2024-12-28 (18 months older than the period end), minus cash 2026-07-04
Enterprise value IRIX
| FY Jan 2026 | $16.8M |
| FY Dec 2024 | $28.1M |
| FY Dec 2023 | $38.9M |
| FY Dec 2022 | $18.5M |
| FY Jan 2022 | $73.4M |
| Jul 2026 | $17.7M |
| Apr 2026 | $15.1M |
| Jan 2026 | $16.8M |
| Sep 2025 | $16.7M |
| Jun 2025 | $10.7M |
| Mar 2025 | $12.2M |
| Dec 2024 | $28.1M |
| Sep 2024 | $28.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-15.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield IRIX
| FY Jan 2026 | -11.2% |
| FY Dec 2024 | -26.3% |
| FY Dec 2023 | -15.0% |
| FY Dec 2022 | -30.5% |
| FY Jan 2022 | +8.3% |
| Jul 2026 | -10.2% |
| Apr 2026 | -14.9% |
| Jan 2026 | -11.2% |
| Sep 2025 | -20.4% |
| Jun 2025 | -39.9% |
| Mar 2025 | -40.5% |
| Dec 2024 | -26.3% |
| Sep 2024 | -23.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing IRIX
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Jan 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-01 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $52.7M | $48.7M | $51.9M | $57.0M |
| Gross profit | $19.2M | $19.5M | $21.8M | $25.4M |
| Operating income | -$2.6M | -$8.3M | -$10.0M | -$7.5M |
| Net income | -$4.4M | -$8.9M | -$9.6M | -$7.5M |
| EPS (diluted) | -0.26 | -0.54 | -0.59 | -0.47 |
| Operating cash flow | -$2.1M | -$7.3M | -$6.7M | -$9.5M |
| Cash | $6.0M | $2.4M | $7.0M | $13.9M |
| Long-term debt | n/a | $1.0M | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
IRIX Stock Sonar score 6/7 axes
Find similar shapesCompareIRIX ranks highest on risk and compliance (82nd percentile) and insider conviction (60th), and lowest on institutional and government (20th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
IRIX filings, in plain words
Are Iridex insiders buying or selling IRIX?
In the 180 days to 2026-10-28, Iridex insiders were net buyers, a net $31.4K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Iridex insiders were net buyers of IRIX, a net $31.4K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
